Detailed Information for C00651

Basic information about inhibitors

IPAD-DB ID C00651
Name Ginsenoside Rb1
Category Natural compounds
2D Structure
3D Structure
Molecular Formula C 5 4 H 9 2 O 2 3
Molecular Weight 1109.3 g/mol
IUPAC Name (2R, 3R, 4S, 5S, 6R)-2-[[(2R, 3S, 4S, 5R, 6S)-6-[(2S)-2-[(3S, 5R, 8R, 9R, 10R, 12R, 13R, 14R, 17S)-3-[(2R, 3R, 4S, 5S, 6R)-4, 5-dihydroxy-6-(hydroxymethyl)-3-[(2S, 3R, 4S, 5S, 6R)-3, 4, 5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-12-hydroxy-4, 4, 8, 10, 14-pentamethyl-2, 3, 5, 6, 7, 9, 11, 12, 13, 15, 16, 17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]-6-methylhept-5-en-2-yl]oxy-3, 4, 5-trihydroxyoxan-2-yl]methoxy]-6-(hydroxymethyl)oxane-3, 4, 5-triol
InChI InChI=1S/C54H92O23/c1-23(2)10-9-14-54(8, 77-48-44(69)40(65)37(62)29(74-48)22-70-46-42(67)38(63)34(59)26(19-55)71-46)24-11-16-53(7)33(24)25(58)18-31-51(5)15-13-32(50(3, 4)30(51)12-17-52(31, 53)6)75-49-45(41(66)36(61)28(21-57)73-49)76-47-43(68)39(64)35(60)27(20-56)72-47/h10, 24-49, 55-69H, 9, 11-22H2, 1-8H3/t24-, 25+, 26+, 27+, 28+, 29+, 30-, 31+, 32-, 33-, 34+, 35+, 36+, 37+, 38-, 39-, 40-, 41-, 42+, 43+, 44+, 45+, 46+, 47-, 48-, 49-, 51-, 52+, 53+, 54-/m0/s1
InChIKey GZYPWOGIYAIIPV-JBDTYSNRSA-N
Canonical SMILES CC(=CCCC(C)(C1CCC2(C1C(CC3C2(CCC4C3(CCC(C4(C)C)OC5C(C(C(C(O5)CO)O)O)OC6C(C(C(C(O6)CO)O)O)O)C)C)O)C)OC7C(C(C(C(O7)COC8C(C(C(C(O8)CO)O)O)O)O)O)O)C
PubChem CID 9898279
DrugBank Accession Number DB06749
CAS Registry Number 41753-43-9

Biological activity data

Ki -
EC50 -
IC50 -
Inhibition -
Toxicity -
ROS(reactive oxygen species) -
Metal Chelating -
BBB(blood-brain barrier) -
Target Protein Aβ1-40
Effects Improve learning and memory capability in AD rats, decrease IL-1β, GFAP, and Aβ expressions in AD rats, increase neurons and Nissl body in hippocampal CA1 area
Research Models In SPF Wistar rats
Main Source Ginseng
Ref. Link

Physicochemical properties

Molecular Weight(Computed by SwissADME) 1109.29
Hac(Computed by SwissADME) 77
Volume(Computed by ADMETlab 2.0) 1073.627
Density(Computed by ADMETlab 2.0) 1.033
nRing(Computed by ADMETlab 2.0) 8
MaxRing(Computed by ADMETlab 2.0) 17
nHet(Computed by ADMETlab 2.0) 23
fChar(Computed by ADMETlab 2.0) 0
nRig(Computed by ADMETlab 2.0) 45
Flexibility(Computed by ADMETlab 2.0) 0.356
Stero Centers(Computed by ADMETlab 2.0) 30
LogS(Computed by ADMETlab 2.0) -1.62
LogD(Computed by ADMETlab 2.0) 1.161

ADMET properties

logP(Computed by ADMETlab 2.0) -0.392
TPSA(Computed by SwissADME) 377.29
Hbond Acceptor(Computed by SwissADME) 23
Hbond Donor(Computed by SwissADME) 15
Rotatable Bonds(Computed by SwissADME)

Pharmacokinetics

GI Absorption(Computed by SwissADME) Low
BBB(blood-brain barrier) Permeant(Computed by SwissADME) No
P-gp Substrate(Computed by SwissADME) Yes
CYP1A2 Inhibitor(Computed by SwissADME) No
CYP2C19 Inhibitor(Computed by SwissADME) No
CYP2C9 Inhibitor(Computed by SwissADME) No
CYP2D6 Inhibitor(Computed by SwissADME) No
CYP3A4 Inhibitor(Computed by SwissADME) No
log Kp(Skin Permeation)(Computed by SwissADME) -12.87

Druglikeness

Lipinski(Computed by SwissADME) 3
Ghose(Computed by SwissADME) 4
Veber(Computed by SwissADME) 2
Egan(Computed by SwissADME) 1
Muegge(Computed by SwissADME) 6
Bioavailability Score(Computed by SwissADME) 0.17